Compare iShares Gold Trust (IAU) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? iShares Gold Trust trades at $78.1 (market cap $60.87B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: iShares Gold Trust is far larger — about 62.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 51 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IAU | MRVI | |
|---|---|---|
Market Cap | $60.87B | $977.37M |
Volume | 4,734,029 | 2,742,564 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $9.00 |
52-Week Low | $74.21 | $2.83 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $78.25, down 0.11% with a bearish technical signal showing 11 sell indicators versus 6 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data has provided some support. Key support and resistance levels cluster around $78-79, indicating consolidation near current levels.
The outlook remains cautious with technical indicators favoring bearish momentum despite neutral oscillators. Investment opportunities exist for contrarian buyers near support levels, but risks include persistent rate hike expectations and dollar strength. The stock requires monitoring of Fed policy signals and Treasury yield movements for directional clarity.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
